SCHEMBL7894076

SCHEMBL7894076

COc1ccc(C(=O)Nc2sc(C)cc2C(=O)O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
CYP1A2 P05177 2/20 0.58
GAA P10253 2/20 0.58
CYP2C9 P11712 2/20 0.58
CYP2C19 P33261 2/20 0.58
HPGD P15428 1/20 0.58
MAPT P10636 4/20 0.56
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
RAB9A P51151 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
KDM4E B2RXH2 3/20 0.56
POLB P06746 1/20 0.56
NPSR1 Q6W5P4 2/20 0.54
PKM P14618 1/20 0.54
NPC1 O15118 4/20 0.52
PTPN5 P54829 1/20 0.52
GLO1 Q04760 1/20 0.52
TP53 P04637 3/20 0.51
ALOX15 P16050 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7894074 0.86 MAPT (0.57) ALDH1A1GAAHPGDMAPTMEN1
SCHEMBL7894867 0.84 MAPT (0.71) ALDH1A1GAAHPGDMAPTMEN1
SCHEMBL5788877 0.84 MAPT (0.60) ALDH1A1GAAHPGDMAPTMEN1
SCHEMBL7904197 0.82 GRIN2C (0.70) ALDH1A1MAPTMEN1KMT2ARAB9A
SCHEMBL7904120 0.82 NPC1 (0.68) ALDH1A1CYP1A2GAACYP2C9CYP2C19
SCHEMBL3484473 0.75 KDR (0.76) ALDH1A1CYP1A2GAACYP2C9CYP2C19
SCHEMBL268017 0.74 KDM4E (0.63) ALDH1A1GAAHPGDMAPTMEN1
SCHEMBL11592884 0.73 NPC1 (0.69) ALDH1A1CYP1A2GAACYP2C9CYP2C19
SCHEMBL21411372 0.73 ALDH1A1 (0.49) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL3593541 0.73 NPSR1 (0.57) ALDH1A1CYP1A2GAACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840527-B2 Non-fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-12-12 US disclosed
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US disclosed
WO-2019154953-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed
US-10273214-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions EMORY UNIVERSITY (US) 2019-04-30 US disclosed
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS TRAYNELIS STEPHEN F (US) 2014-09-18 US disclosed
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS TRAYNELIS STEPHEN F (US) 2014-09-18 US disclosed
US-8822462-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions EMORY UNIVERSITY (US) 2014-09-02 US disclosed
US-8822462-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions EMORY UNIVERSITY (US) 2014-09-02 US disclosed
US-20120028977-A1 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions EMORY UNIVERSITY (US) 2012-02-02 US disclosed
US-20120028977-A1 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions EMORY UNIVERSITY (US) 2012-02-02 US disclosed
WO-2010088414-A2 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS EMORY UNIVERSITY (US) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10273214-B2 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions GRIN1, GRIN2A, GRIN2B ALDH1A1 2048/4885CYP1A2 2818/4885GAA 600/4885
US-20120028977-A1 Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions GRIN1, GRIN2A, GRIN2B ALDH1A1 2048/4885CYP1A2 2818/4885GAA 600/4885
US-20140275529-A1 SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS GRIN1, GRIN2A, GRIN2B ALDH1A1 2048/4885CYP1A2 2818/4885GAA 600/4885
US-20200369655-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH ALDH1A1 1977/4885CYP1A2 1926/4885GAA 498/4885
US-11840527-B2 Non-fused thiophene derivatives and their uses FTH1, SLC40A1, FECH ALDH1A1 1977/4885CYP1A2 1926/4885GAA 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.